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Abstract
Background: The risk of squamous intra-epithelial lesions (SIL) is higher in HIV-positive women. As these women begin to
live longer due to highly active antiretroviral therapy (HAART), their risk of cervical cancer may increase. Few data exist regarding
the effect of HAART on the incidence and progression of SIL in HIV-positive African women. The aim of this study was to evaluate
the effect of HAART on the incidence and progression of SIL in HIV-positive women in South Africa.
Methods: A prospective observational study of HIV-seropositive women was conducted over 5 years in an HIV treatment clinic
in Johannesburg, South Africa. The participants consisted of 601 women on and off HAART who had repeat Pap smears greater
than 6 months apart. The effect of HAART use on incidence and progression rates of SIL was determined using multivariate
Poisson regression to obtain incidence rate ratios (IRRs), adjusted for age, CD4 count and other potential confounders.
Results: Median follow-up time was 445 days (inter-quartile range 383, 671). The crude rate of incidence of any SIL was
15.9 episodes (95% confidence limit (CL) 12.7, 19.9) per 100 person-years; the crude rate of all progression of cervical dysplasia
among women was 13.5 episodes (95% CL 11.3, 16.1) per 100 person-years. HAART use was associated with a robust reduction
in the rate of incidence and progression of cervical lesions, adjusted IRR0.55 (95% CL 0.37, 0.80). Sensitivity analyses
confirmed this main association held for incidence and progression when they were considered separately, and that the result
was not dependent on the length of HAART exposure.
Conclusion: HAART use was associated with a reduction in the rate of both incidence and progression of cervical lesions among
HIV-positive women.
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Background
HIV-positive women in sub-Saharan Africa have a higher
prevalence of cervical squamous intra-epithelial lesions (SIL)
and invasive cervical cancer than HIV-positive women in
other regions of the world [13]. Women with lower CD4
counts consistently have higher rates of high-grade squa-
mous intra-epithelial lesions (HSIL) [1,2]. The prevalence of
high-risk human papillomavirus (HPV) infection, the etiologic
agent of cervical cancer, is high in sub-Saharan Africa [4,5].
HPV infections persist longer in HIV-positive women [6,7].
Limited access to cervical cancer screening programmes in
this region of the world places women at an increased risk for
the development of cervical cancer.
With increasing access to highly active antiretroviral
therapy (HAART) through governmental and donor organiza-
tions, HIV-positive women in resource limited countries
are living longer as deaths from opportunistic infections
decline [8]. HAART use has been shown to reduce the risk of
opportunistic malignancies such as Kaposi sarcoma and some
lymphomas [9,10]. However, the relationship between the
use of HAART and the development of cervical lesions
remains unclear, with some studies showing benefit with
HAART [11,12] and others showing no benefit [13,14].
At present, there are few data examining the impact
of HAART on the natural history of cervical lesions from
the region of sub-Saharan Africa with the highest prevalence
of both cervical cancer and HIV. We present results here
on the relationship of HAART use and cervical lesions from
an observational study of HIV-positive women from a public
sector HIV treatment clinic in Johannesburg, South Africa.
Methods
Study population and enrolment
An observational longitudinal study of HIV-positive women
was conducted within the South Africa Cervical Cancer
Cohort (SACCC) [1]. The cohort included HIV-positive women
aged from 18 to 65 who were recruited from an adult
HIV outpatient clinic in a teaching hospital affiliated with
the University of Witwatersrand in Johannesburg. Women
were eligible to participate in this study unless they (1) were
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pregnant; (2) had undergone a hysterectomy or cone biopsy;
(3) were severely ill per investigator’s opinion; or (4) had
signs/symptoms suggestive of a sexually transmitted infec-
tion (STI). Women were study-eligible following the treat-
ment of any symptomatic STI, and 6 weeks after the end
of pregnancy. Women were also eligible to participate in
this study if they had two Pap smears 6 months apart.
After an educational session was presented on cervical
cancer screening in English or in an appropriate African
language, women were invited for a conventional Pap
smear and to participate in this observational study. Health
workers screened for exclusion criteria, explained study aims,
and obtained written informed consent. A medical history
was obtained through a participant interview including
information on demographics characteristics, antiretroviral
therapy status, and lifestyle factors, including smoking/snuff
(traditional chewing tobacco), reproductive/menstrual char-
acteristics, previous Pap smear results if applicable, sexual
history/behaviour, history of STIs and contraceptive use.
All protocols were reviewed and cleared by the Human
Ethics Committee (Medical) of the University of the Witwa-
tersrand and, for secondary data analyses, by the University
of North Carolina.
Laboratory analysis
During a pelvic examination, cervical exfoliated cells were
collected using an endo-cervical brush for a conventional Pap
smear diagnosis. Conventional cervical smears were per-
formed as standard of care for HIV-positive women in South
Africa. Liquid-based cytology is currently not available in the
government sector of care in South Africa. Cytology slides
were read and analyzed according to Bethesda 2001 guide-
lines [15]. Women with HSIL and atypical squamous cells-
high (ASC-H) were referred to immediate colposcopy
[16]. Women with atypical squamous cells of undetermined
significance (ASCUS) or low-grade squamous intra-epithelial
lesions (LSIL) were followed with a repeat Pap smear after
1 year per standard of care in South Africa if their CD4
count was above 200 cells/mm3 or after 6 months if their
CD4 count was 200 cells/mm3 or below. Women were
also referred for colposcopic biopsy if they presented with
three consecutive LSIL results over 18 months or greater. For
quality control, 10% of the conventional cytology slides were
sent to the University of North Carolina for blinded double
readings on two occasions, with an observed concordance
rate of 81% and 85% [1]. HIV-positive women were treated
according to the South African guidelines on Comprehensive
HIV and AIDS Care, Management and Treatment [17], by
which at the time of the study HAART was initiated at WHO
Stage 4 or CD4 counts of B200 cells/mm3.
Statistical methods
Women with two Pap smears at least 6 month apart were
included in data analyses. In the main analysis, ASC-US
results were classified as LSIL results, while ASC-H results
were classified as HSIL results; alternatives were explored in
sensitivity analysis. Outcome was defined as the time to the
first incidence or first progression of cervical dysplasia from
baseline status, that is, from negative Pap smear to LSIL, HSIL,
or cancer; or from LSIL to HSIL or cancer. A HSIL diagnosis
resulted in treatment (specifically, a loop electrosurgical
excision procedure (LEEP)). Because individuals with HSIL
at baseline were not at risk of cervical lesion progression in
the same way as those with negative or LSIL diagnoses due
to treatment, HSIL cases were excluded from analyses of
progression.
The main analyses examined the effect of HAART at
the time of first Pap smear (baseline) on the rate of incidence
or progression of cervical lesions. The main analyses were
intent-to-treat, in that changes in exposure after baseline
were not considered. These analyses used multivariate
Poisson regression to compare the rate of incidence and
progression of any SIL using HAART at baseline to no HAART
at baseline. All analyses considered confounding by age,
CD4 count, age at first intercourse, lifetime number of sexual
partners, history of STI, use of hormonal contraception,
condom use at last sex, employment status, current smoking,
snuff use (traditional chewing tobacco) and education
level. CD4 counts and age were both modelled as four-knot
restricted cubic splines; other covariates were modelled
categorically. Last, we evaluated the modification of the
effect of HAART by CD4 counts by including an inter-
action term with dichotomized CD4 count (]350 cells/mm3,
B350 cells/mm3) in the multivariate model.
Results
Cohort characteristics
There were 601 women eligible for analyses. Median
follow-up time among these women was 455 days (inter-
quartile range (IQR) 385, 704) between baseline visit and
end of follow-up (at either time of event or last follow-up
visit without an event). Of the 601 women, 122 (17%) of
women experienced an incident cervical lesion or a progres-
sion event; the median time to incidence or progression
in these women was 407 days (IQR 361, 622). Among
women with an incident lesion or lesion progression receiv-
ing HAART (n75), the median time to incident lesion/
progression was 420 days (IQR 362, 682); among women
not receiving HAART (n47), the time to incidence/
progression was 390 days (IQR 357, 494) (Wilcoxon rank-
sum test p0.18).
Of the 601 participating women, 54% (n326) had a
negative Pap at baseline, and 46% (n275) had baseline
LSIL; these baseline proportions of cervical lesions did not
vary by baseline HAART status (chi-square test for non-zero
correlation, p0.37). Women included in the study had
a median age of 35 years (IQR 31, 41), and approximately
a third (37%) of these women had a CD4 count under
200 cells/mm3 at baseline. Over two-thirds of women were
receiving HAART at their first visit (n424, 71%). Median
time on HAART was 0.92 years (IQR 0.36, 1.74). Table 1
presents additional baseline demographics of these 601
women stratified by baseline HAART status.
Crude risks of incidence and progression
Among individuals who had a negative Pap baseline status,
the crude rate of incidence of LSIL, HSIL, or invasive cancer
was 15.9 (95% confidence limit (CL) 12.7, 19.9) episodes
per 100 person-years. Among those with LSIL at baseline, the
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crude rate of progression to higher stages of cervical lesions
was 10.8 (95% CL 8.1, 14.4) per 100 person-years.
The crude combined rate for first incidence or progression
was 13.5 (95% CL 11.3, 16.1) per 100 person-years; these and
other crude incidence and progression rates are summarized
in Table 2. Crude incidence and progression rates differed
by the CD4 count, as shown in Table 3. The CD4 count
significantly affected the rates of progression of cervical
dysplasia. Progression rates were quite marked in women
with CD4 counts of B50 cells/mm3 and were lower when
CD4 counts were 350 cells/mm3 (Table 3) in women with
both negative and LSIL baseline Pap smears. The test for
linear trend of progression rate by CD4 category was
p0.08.
Effect of HAART on incidence and progression
In the main analysis of the effect of HAART use at first
visit on the rate of first incidence or progression of cervical
dysplasia, the crude Poisson model resulted in an estimated
incidence rate ratio (IRR) of 0.63 (95% CL 0.43, 0.90); that
is, women receiving HAART at the time of first visit had
0.63 times the combined rate of cervical dysplasia incidence
and progression when compared with women not receiving
HAART at first visit. Results from a multivariate analysis were
stronger than the crude analyses, yielding an adjusted rate
ratio of 0.55 (95% CL 0.37, 0.80). Sensitivity analyses
confirmed main results; results were essentially identical
when restricting to analysis of incidence or progression only,
when excluding those with ASCUS results, and when using a
Cox proportional hazards model. These results are summar-
ized in Table 4. In addition, we conducted a sensitivity
analysis and adjusted results for the time on HAART, and
progression results were similar, rate ratio0.54 (95% CL
0.37, 0.80).
The effect of baseline HAART exposure was strongly
modified by baseline CD4 count (Table 4). Among those
with CD4 counts of B350 cells/mm3, the rate ratio was
0.47 (95% CL 0.30, 0.73). Among those with baseline CD4
Table 1. Characteristics of 601 HIV-positive women by baseline exposure to HAART at study entry
HAART (n424) No HAART (n177)
No. % No. % p Valuea
Ageb 35 (31, 41) 34 (30, 41) 0.094
Parityb 2 (1, 3) 2 (1, 2) 0.131
CD4 count (cells/mm3)b 248 (152, 382) 299 (174, 448) 0.009
CD4 count (cells/mm3)
B200 166 39.2 52 29.4 0.036
200349 124 29.3 52 29.4
]350 134 31.6 73 41.2
Baseline negative Pap 225 53.1 101 57.1 0.371
Reported history of STIs 292 68.9 113 63.8 0.231
Condom used at last sex 317 74.8 126 71.2 0.364
Current hormonal contraception 60 14.2 16 9.0 0.086
Lifetime # sex partners ]5 179 42.2 61 34.5 0.077
Age at first sex B15 years 34 8.0 12 6.8 0.603
Unemployed 235 55.4 86 48.6 0.126
High school graduate 174 41.0 64 36.2 0.265
STIs, sexually transmitted infections.
aCategoric variables are compared by chi-square test for general association; continuous variables by Wilcoxon rank-sum test; bmedian (inter-
quartile range).
Table 2. Crude cervical dysplasia progression counts and rates by baseline and follow-up Pap result among 601 HIV-positive women
in Johannesburg, South Africa
From To No. of progressions Progression ratea 95% CL
Negative or LSIL Any higher 122 13.5 11.3, 16.1
Negative LSIL, HSILb 76 15.9 12.7, 19.9
Negative LSIL 68 14.6 11.5, 18.5
Negative HSIL 8 2.1 1.0, 4.2
LSIL HSIL 46 10.8 8.1, 14.4
CL, confidence limit; HSIL, high-grade squamous intra-epithelial lesion; LSIL, low-grade squamous intra-epithelial lesion.
aProgression rates given per 100 person-years; bHSIL: HSIL and invasive cervical cancer.
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counts of ]350 cells/mm3, the rate ratio was 0.84 (95% CL
0.42, 1.72).
Discussion
Our study presents some of the first information on the
effect of HAART on the incidence and progression of cervical
lesions among HIV-positive women in sub-Saharan Africa.
HAART is associated with a sizable reduction in the combined
rate of incident lesions and the progression of any SIL in HIV-
positive women in this population, as well as with incidence
and progression of any SIL considered separately.
Observed rates of overall first incidence or progression of
cervical lesions are higher (at 13.5 per 100 women-years)
than in studies of HIV-positive women from other countries.
One pre-HAART study in the United States found lower rates
of incidence of histologic-proven SIL, 8.3 per 100 person-
years (95% CL 6.5 to 10.6) [14]. Another study of the US
women with histologic-proven cervical intra-epithelial neo-
plasia 1 (CIN-1) found a very low rate of progression to HSIL
or greater, 1.2 per 100 person-years (95% CL 0.5, 2.4) [18].
Higher rates observed in this cohort may be explained in part
by lower CD4 cell counts in our cohort (median 267 cells/
mm3), in contrast to the US and European cohorts (medians
typically above 350 cells/mm3) [14, 1820]. Moreover, 70%
of this cohort was on HAART, implying lower CD4 counts in
the past for most women [21]. Another possible contributor
to higher rates is the deficiency in folate and B12 tocopherols
among South African women [22], which is thought to
increase the risk of cervical dysplasia [2325].
Data on the relationship between HAART and progression
of cervical disease have been inconsistent [2632]; a study
of HIV-positive Italian women found no beneficial effect of
HAART therapy on the risk of incident or progression rates
of SIL [26], while a US-based study found that women on
HAART had an increased clearance of HPV infection, though
not with cervical cytologic regression or progression [27].
In contrast, our results are largely consistent with the
Women’s Interagency HIV study cohort, which found that the
use of adherent HAART was associated with lower detection
of incident oncogenic HPV (hazard ratio (HR) 0.49; 95% CL
0.30, 0.82) and an improved clearance rate of oncogenic HPV
and SIL (HR 2.4; 95% CL 1.1, 5.2) [28]. A second Italian
cohort also showed that HAART significantly reduced the risk
of developing CIN (HR 0.3; CL 0.13, 0.68) [29]. A recently
published South African study also found that women on
HAART had a reduced risk of progression of cervical
neoplasia, albeit with a smaller magnitude of effect than
observed in our study (HR 0.72; 95% CL 0.52, 0.99) [30].
Differences in the magnitude of the effect of HAART on the
incidence/progression of SIL in different cohorts may be due
to the differences in adherence to HAART [28]. Adherence to
HAART in our clinic, as measured by HIV virologic suppres-
sion, was 90% at 6 months and 85% at 1 year follow-up [21].
Another potential reason for the different magnitudes of
the HAART effect on SIL incidence/progression might be
related to the average baseline CD4 counts of the partici-
pants in these studies. This is consistent with the observation
that immunosuppression is a risk factor for acquiring cervical
dysplasia [1,2]. Our study shows that rates of incidence or
progression of cervical lesions were higher with lower CD4
counts and that HAART had a stronger effect on reducing the
rate of progression at lower CD4 counts. Two additional
analyses from a cohort in Spain are consistent with our
Table 3. Crude rates of cervical dysplasia incidence and progression by baseline CD4 count among 601 HIV-positive women in
Johannesburg, South Africa
Incidence or progression Incidence only Progression only
CD4 counta Rateb 95% CL Rateb 95% CL Rateb 95% CL
B50 18.0 10.0, 32.6 25.8 12.9, 51.5 10.0 3.2, 31.0
50199 15.4 11.4, 20.8 18.8 12.0, 29.5 13.4 8.9, 20.2
200349 13.5 9.7, 18.7 18.1 12.2, 26.7 8.6 4.7, 15.5
]350 10.8 7.7, 15.2 11.6 7.8, 17.3 9.3 4.8, 17.8
CL, confidence limit.
aUnit: cells/mm3; brates per 100 person-years.
Table 4. Estimates of the effect of HAART on rate of incidence
and progression of cervical dysplasia among 601 HIV-positive
women in Johannesburg, South Africa
Rate ratio 95% CL
Crude 0.63 0.43, 0.90
Adjusteda 0.55 0.37, 0.80
Modification by CD4 counta
CD4B350 cells/mm3 0.47 0.30, 0.73
CD4 ] 350 cells/mm3 0.85 0.42, 1.72
Sensitivity analysesa
Incidence only 0.55 0.34, 0.90
Progression only 0.52 0.27, 1.01
Excluding ASC-US 0.59 0.38, 0.90
Cox PH modelb 0.45 0.30, 0.67
CL, confidence limit.
aAdjusted for age, CD4 count, age at first intercourse, lifetime
number of sexual partners, history of sexual transmitted diseases,
use of hormonal contraception, condom use at last sex, employment
status, current smoking, snuff use (traditional chewing tobacco) and
education level; bthe Cox proportional hazards model yields an
adjusted hazard ratio, not an adjusted rate ratio.
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results. A retrospective study from Spain showed that
women on HAART with controlled HIV disease (defined
as an undetectable HIV viral load and a CD4 count of
200 cells/mm3) had a reduction in SIL. The significant
effect of HAART was seen in women with CD4 counts of
B350 cells/mm3 as there was no difference seen in the
effect of HAART on any SIL with women with CD4 counts
of 350 cells/mm3 [31,32]. The stronger relationship of
HAART’s effect in lower CD4 ranges may be due to the
significant immunosuppression in patients with CD4 counts
of B350 cells/mm3. This is an important finding as the
median CD4 count of patients coming to our clinic is
76 cells/mm3 (IQR 28, 136) [33], thus potentially explaining
why HAART treatment reduced the progression of dysplasia
in our population in South Africa. Immune reconstitution
of HAART, however, is often incomplete, especially in
populations that initiate HAART at a CD4 count below
200 cells/mm3 [34,35] as per the South Africa guidelines
during this study [17]. Even in patients with successful
immune reconstitution measured by CD4 counts, the risk
for opportunistic infections such as tuberculosis is still higher
than that among the HIV-seronegative population [36,37].
Future research should consider CD4-stratified effect esti-
mates to help clarify these issues and to evaluate if women
with complete immune reconstitution are still at higher risk
of SIL progression than HIV-negative women. In addition, in
resource-limited countries especially where access to cervical
cancer screening programmes are limited, initiating women
on to HAART should be strongly considered especially among
women with CD4 counts of B350 cells/mm3.
The strengths of this study include that it was conducted in
a government HIV treatment clinic, allowing results to be
extrapolated more closely to the actual clinical environment
in which our women are seen, relatively large sample size
and long follow-up.
This work has several limitations. First, histologic verifica-
tions of Pap smears are lacking. Colposcopic biopsies in
women with negative or a single LSIL Pap is not standard of
care in South Africa; however, Pap smears from this cohort
were independently reviewed as noted previously. We also
did not control for other factors such HIV viral load, real-time
STI and HPV infection status. Baseline HIV viral load
information is not routinely collected in South Africa at
HAART initiation [17]. HPV testing was not done in this study
as it is not available in South African government hospitals or
clinics. The history of recent STI was per patient recall on our
questionnaire making the timing and accuracy of diagnosis of
STI difficult to ascertain. Laboratory testing for STI in the
government system in South Africa is not performed, and
treatment is based on clinical symptoms.
One additional limitation is the relative poor sensitivity of
cytology, potentially leading to an under-diagnosis of LSIL
at baseline. This misclassification would cause us to over-
estimate the incidence of LSIL. However, such misclassifica-
tion is likely to be independent of current HAART status and
is, therefore, likely to be non-differential misclassification. If
so, then our reported incidence rate ratio is likely (though not
guaranteed) to underestimate the true effect of HAART on
incidence or progression of cervical dysplasia. Of course, if
such misclassification depends on HAART status, the effects
are more difficult to predict.
Conclusions
This study demonstrates high baseline rates of incidence
and progression of cervical lesions among HIV-positive
women in South Africa, as well as the effect of HAART at
reducing risks of both incidence and progression. Given
that the median time to an incidence or progression event
was 407 days, yearly cervical cancer screening should be
considered for HIV-positive women. WHO HIV 2010 revised
treatment guidelines recommend resource-limited countries
initiate HAART in HIV-positive patients with CD4 counts of
B350 cells/mm3 in WHO Stage 1 and 2 [38]. Our data suggest
a potential benefit of initiating HAART use in these women at
CD4 counts of B350 cells/mm3. Integrating cervical cancer
screening programmes into HIV treatment programmes is a
public health imperative in South Africa.
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